Background {#Sec1}
==========

Hypertension is a major global public-health challenge affecting approximately 1 billion individuals worldwide, with a projection to increase to 1.56 billion by 2025 given the increasingly aging population \[[@CR1]\]. Hypertension is a disease with significant clinical and socio-economic consequences. Globally, cardiovascular diseases account for approximately 17 million deaths per year. More than a half of these cases are due to complications resulting from hypertension \[[@CR2], [@CR3]\]. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure describes the relationship between BP and risk of cardiovascular disease (CVD) as "continuous, consistent, and independent of other risk factors" \[[@CR4]\]. The chances of heart attack, heart failure, stroke, and kidney diseases increase with BP increments. Meta-analysis of observational studies showed that the risk of cardiovascular death increases continuously from BP levels of 115 mmHg systolic and 75 mmHg diastolic \[[@CR5]\].

The reduction in cardiovascular mortality and morbidity in patients treated for hypertension is directly related to the magnitude of blood pressure reduction. The utility of diuretics in the prevention of cardiovascular complications has been shown in major clinical trials \[[@CR4]\], and these agents have a long history of safety and efficacy \[[@CR6], [@CR7]\]. Thiazide-like/type diuretics, such as chlorthalidone (CTLD) and hydrochlorothiazide (HCTZ), respectively, are important options for use in uncomplicated hypertension, without the presence of comorbid conditions. There has been debate about whether thiazide-like diuretics such as chlorthalidone and indapamide should be given preference over classical thiazide diuretics (e.g., hydrochlorothiazide and bendrofluazide), but their superiority on outcomes has never been tested in head-to-head RCTs \[[@CR8]\]. For instance, CTLD is 1.5 to 2.0 times more potent than HCTZ on an mg:mg basis, and has a considerably longer half-life (45--60 h vs 8--15 h) and duration of action (48--72 h vs 16--24 h) after long-term dosing. Meta-analyses also suggest that CTLD is superior to HCTZ in preventing cardiovascular events \[[@CR9], [@CR10]\]. A meta-analysis \[[@CR11]\] and a network meta-analysis (being prepared for publication) performed by our team also point to a prevalence for CTLD with regard to systolic and diastolic blood pressure control.

However, many treated hypertensive patients have inadequate blood pressure control and do not attain treatment goal \[[@CR12], [@CR13]\]. Although a single antihypertensive agent is considered to be the ideal in terms of convenience and compliance, many patients with essential hypertension require a combination drug regimen \[[@CR14], [@CR15]\].

Combination therapy with a renin-angiotensin system (RAS) inhibitor (either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker \[ARB\]) plus a diuretic is a widely used and effective approach that has become an established component of evidence-based hypertension treatment guidelines \[[@CR16]--[@CR18]\]. The combination of an ARB with a thiazide diuretic has been shown to be efficacious and well tolerated in numerous clinical trials \[[@CR19]--[@CR29]\]. This combination could be of particular value in hypertensive patients with additional cardiovascular risk factors or in populations whose BP is traditionally poorly controlled, such as elderly persons, persons with diabetes mellitus and black patients \[[@CR19], [@CR30]\]. However, the question of which diuretic---chlorthalidone or hydrochlorothiazide has not been widely discussed.

Materials and methods {#Sec2}
=====================

Main aim {#Sec3}
--------

The main aim for this meta-analysis is to compare the efficacy of the combination of angiotensin receptor blocker and chlorthalidone to the effect of the combined use of angiotensin receptor blocker and hydrochlorothiazide in adult patients with hypertension.

Data sources and search strategy {#Sec4}
--------------------------------

A comprehensive literature search was conducted through electronic databases: Cochrane, eLIBRARY.ru, MEDLINE, PsyInfo, PubMed, Scopus, and registries for data of clinical trials ([http://ClinicalTrials.gov](http://clinicaltrials.gov) and <http://www.clinicaltrialsregister.eu>) in September 2018 to identify studies that investigate the effect of the combination of angiotensin receptor blocker with chlorthalidone or hydrochlorothiazide on the systolic and diastolic blood pressure in patients with hypertension. The following keywords and various combinations were used in the search: *hydrochlorothiazide*, *chlorthalidone*, *diuretics*, *ARB*, *angiotensin receptor blocker*, *hypertension*, *blood pressure*, *clinical trial*, *controlled*, *randomi\**, *double blind.* Results were not limited only to those in English. Similar key words and their combinations were used in Cyrillic: *гидрохлортиазид*, *хлорталидон*, *диуретики*, *AR блокеры*, *ARB*, *повышеное давление*, *артериальная гипертензия*, *кровяное давление*, *артериальное давление*, *клиническое испытание*, *клиническое исследование*, *контролированное*, *рандомизированное*, *двойное слепое*. Unfortunately, results in Cyrillic were not found. Full-text articles and abstracts were checked for relevance to the topic and were assessed. Generally, we did not restrict the search period but relevant articles were mainly published in the 1980-2020 period.

Inclusion criteria {#Sec5}
------------------

Search results were assessed for relevance on the basis of the following inclusion criteria: (1) type of study/trial---epidemiologic, controlled, and randomized; (2) investigation of the effect the combination of angiotensin receptor blocker with chlorthalidone or hydrochlorothiazide on the systolic and diastolic blood pressure; (3) type of subjects included---representatives of the whole population or a specific stratum; (4) patients with essential hypertension; (5) access to raw data; (6) eligibility for statistical analysis. If any clarification of results or conclusions was needed, authors were contacted for additional information. We have not limited our search to a particular angiotensin receptor blocker but have attempted to review the group as a whole. Sources were excluded if they represented trials in which the principle arm reported other outcomes different from changed in systolic and diastolic blood pressure; other conditions apart from hypertension; other combinations of CTLD and HCTZ (for example with calcium channel blockers and angiotensin converting enzyme inhibitors).

Quality assessment {#Sec6}
------------------

Effective public health practice project was utilized to assess study quality. This tool includes assessment of different characteristics like selection bias, study design, blinding, data collection method, confounders, and drop outs in order to help raters form an opinion of quality based upon information contained in the study. Studies that correspond to the aforementioned inclusion criteria are subjected to a quality estimation and general ratings are taken into account when results from the study are interpreted. Overall quality of evidence for the two primary outcomes was assessed according to Grade methodology.

Data extraction and statistical analysis {#Sec7}
----------------------------------------

All relevant studies identified were carefully reviewed, sorted, and assessed. Figure [1](#Fig1){ref-type="fig"} depicts the process of selection applied to evaluated studies in order to determine their eligibility for inclusion in the analysis. Extracted data encompassed publication year, type of study, ARB used, type of population, duration of study, number of patients, doses used of the ARB and the diuretic. Additionally, data about measurements of systolic and diastolic blood pressure were extracted separately in Excel. Data for systolic and diastolic blood pressure was presented as weighed mean difference with a 95% confidence interval (CI). Fig. 1Flow chart of study selection process

Because of the significant heterogeneity of the individual studies, we chose the random-effects method as the primary analysis. To assess the aforementioned heterogeneity of treatment effect among trials, we used the Cochran *Q* and the *I*2 statistics, where *p* values of less than 0.10 were used as an indication of the presence of heterogeneity and an *I*2 parameter greater than 50% was considered indicative of substantial heterogeneity \[[@CR31]\]. The threshold for statistical significance was set at 0.05. Forest plots depict estimated results from the studies included in the analysis. Funnel plots were used to evaluate publication bias (not shown in the main manuscript, but provided as [Supplementary material](#MOESM1){ref-type="media"}). Sensitivity analyses were performed in order to evaluate the degree of influence of the consequent elimination of each individual study on the final result. Calculations were made with MetaXL ver 5.3 (add-ins of MSExel).

Results {#Sec8}
=======

Our search returned 2745 titles. Once duplicate reports and studies not relevant to the analysis were excluded, 51 full text articles remained to be subjected to assessment. After evaluation based on the inclusion criteria described in the methods, only 15 studies presenting data for 28 separate dose regimens remained to be included in the analysis comparing the efficacy of the combination of angiotensin receptor blocker and chlorthalidone to the effect of the combined use of angiotensin receptor blocker and hydrochlorothiazide in patients with hypertension (Fig. [1](#Fig1){ref-type="fig"}).

Characteristics of the studies included in the meta-analysis are outlined in Table [1](#Tab1){ref-type="table"} and data about baseline systolic and diastolic blood pressure is presented in Table [2](#Tab2){ref-type="table"}. All 15 studies \[[@CR20]--[@CR29], [@CR32]--[@CR36]\] are randomized and all but 3 \[[@CR23], [@CR27], [@CR36]\] are double blinded. There are 10 studies comparing ARB/HCTZ with HCTZ \[[@CR20]--[@CR22], [@CR24]--[@CR29], [@CR32]\], one study comparing ARB/CTLD with CTLD \[[@CR33]\] and 4 studies comparing ARB/CTLD with ARB/HCTZ \[[@CR23], [@CR34], [@CR36]\]. In 4 studies, the ARB used is olmesartan \[[@CR20], [@CR34]--[@CR36]\], in 3 \[[@CR21], [@CR26], [@CR27]\] it is valsartan, in 3 \[[@CR22], [@CR23], [@CR27]\] it is candesartan, and in 3 it is telmisartan \[[@CR24], [@CR25], [@CR27]\]. There is one study discussing each of the following: fimasartan \[[@CR28]\], eprosartan \[[@CR29]\], and losartan \[[@CR32]\]. Azilsartan is used for treatment in 4 studies \[[@CR33]--[@CR36]\]. Most commonly studies last 8 weeks although Cushman et al. \[[@CR34]\] and Makita et al. \[[@CR27]\] use duration of 12 weeks, Fogari et al. \[[@CR20]\]---16 weeks, and Neutel et al. \[[@CR36]\]---52 weeks. The number of patients involved varies a lot between studies but as a whole 2515 patients are treated with angiotensin receptor blocker, 4095 are treated with the combination of ARB/HCTZ, and 2795 are treated with the combination ARB/CTLD. The quality of the studies has been estimated as poor, moderate, or strong using the effective public health practice project. Results are presented in Table S[1](#MOESM1){ref-type="media"} the Supplementary material. Table 1Study characteristicsAuthor, yearType of studyARB usedType of populationDuration of studyNumber of patientsDoses, mgARBHCTZ + ARBCTDN + ARBARBHCTZ + ARBCTDN + ARBFogari et al., 2010 \[[@CR20]\]Randomized, double-blind, parallel-group, up-titration, multicenter, multinational, phase IIIOlmesartanModerate to severe hypertension, male or female patients, mean age 55.616 weeks2855564040/12.5, 40/25Benz et al., 1998 \[[@CR21]\]Randomized, double-blind, multiple dose, placebo controlled, multifactorial, parallelValsartanUncomplicated essential hypertension, male or female patients, mean age 52 (22-86)8 weeks198 (99, 99)379 (96, 92, 97, 94)80, 16080/12.5, 80/25, 160/12.5, 160/25Edes, 2009 \[[@CR22]\]Randomized, double-blind, parallel-group studyCandesartanMild to moderate primary hypertension, male or female patients, mean age 538 weeks, 4 weeks follow-up4654923232/25Kwon et al., 2013 \[[@CR23]\]Open-label, randomized, prospective cross-over studyCandesartanNever treated primary hypertension, male or female patients, mean age 508 weeks25 (4 weeks)151388/258/12.5Lacourciere and Martin, 2002 \[[@CR24]\]Prospective, randomized, double-blind, parallel-group studyTelmisartanMild-to-moderate essential hypertension, male or female patients, mean age 54.1 (28-79)8 weeks1671604040/12.5Lacourciere et al., 2001 \[[@CR25]\]Multicenter, prospective, randomized, double-blind, parallel-group studyTelmisartanMild-to-moderate, essential hypertension and inadequate BP control, male or female patients, mean age 55.6 (20-79)8 weeks2452468080/12.5Lacourciere et al., 2005 \[[@CR26]\]Randomized, double blind, 3-arm, parallel group studyValsartanStage 2 or 3 systolic hypertension (SBP ≥ 160 mmHg and ≤ 200 mmHg) with or without other CV risk factors, male or female patients, mean age 60.88 weeks261513 (258, 255)80, 160160/12.5, 160/25Makita et al., 2009 \[[@CR27]\]Randomized, parallel-group studyCandesartan/valsartan vs telmisartanHypertensive outpatients treated with an ARB, candesartan or valsartan, male or female patients, mean age 69.312 weeks32328 or 8040/12.5Rhee et al., 2015 \[[@CR28]\]Multicenter, randomized, active-controlled, double-blind, parallel-group, dose-titration trialFimasartanMild to moderate primary hypertension, male or female patients, mean age 55.38 weeks881756060/12.5Sachse et al., 2002 \[[@CR29]\]Multicenter, prospective, randomized, double-blind, parallel group studyEprosartanMild to moderate primary hypertension, male or female patientsmean age 58.78 weeks, 4 weeks follow-up157152600600/12.5MacKay et al., 1996 \[[@CR32]\]Multicenter, randomized, double-blind, parallel-group studyLosartanEssential hypertension, male or female patients, mean age 55 (22-79)8 weeks, 4 weeks follow-up122125, 1145050/6.25, 50/12.5Sica et al., 2012 \[[@CR33]\]Phase 3, randomized, double-blind, factorial studyAzilsartanMild to moderate primary hypertension, male or female patients, mean age 578 weeks470 (155, 153, 162)928 (156, 147, 153, 154, 156, 162)20, 40, 8020/12.5, 40/12.5, 80/12.5, 20/25, 40/25, 80/25Cushman et al., 2012 \[[@CR34]\]Randomized, double-blind, forced-titration studyAzilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazidePrimary hypertension, male or female patients, mean age 5712 weeks364355, 35240/2540/25, 80/25Cushman et al., 2018 \[[@CR35]\]Randomized, double-blind, parallel-group studyAzilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazidePrimary hypertension, male or female patients, mean age 578 weeks356372, 35740/2540/25, 80/25Neutel et al., 2017 \[[@CR36]\]Phase 3, randomized, parallel-group, open-label, multicenter, multinational studyAzilsartan+ chlorthalidone; olmesartan+ hydrochlorothiazideStage 2 essential hypertension, male or female patients, mean age 58.5 (\> 45)52 weeks41941840/2580/25Note: Mild to moderate hypertension stands for stage I and stage II hypertension according to "2017 High Blood Pressure Clinical Practice Guideline"Normal: Systolic \< 120 and diastolic \< 80 mmHgElevated: Systolic between 120 and 129 and diastolic \< 80Stage 1: Systolic between 130 and 139 or diastolic between 80 and 89Stage 2: Systolic ≥ 140 or diastolic ≥ 90 mmHgTable 2Baseline systolic and diastolic blood pressureAuthor, yearSBPDBPARBHCTZ + ARBCTDN + ARBARBHCTZ + ARBCTDN + ARBFogari et al., 2010 \[[@CR20]\]168.1 ± 7.6168.5 ± 8.4104.5 ± 4.0104.6 ± 4.2Benz et al, 1998 \[[@CR21]\]153.7 ± 14.4153.5 ± 15.1153.0 ± 14.0154.5 ± 15.4152.0 ± 14.2155.9 ± 14.8101.5 ± 4.9101.5 ± 4.8101.0 ± 4.9101.0 ± 4.5100.4 ± 4.6101.4 ± 4.8Edes, 2009 \[[@CR22]\]152.9 ± 12.8154.0 ± 13.197.4 ± 5.697.5 ± 5.6Kwon et al., 2013 \[[@CR23]\]153 ± 13128 ± 14131 ± 1294 ± 881 ± 1184 ± 9Lacourciere and Martin, 2002 \[[@CR24]\]146.7 ± 12.7147.1 ± 13.695.6 ± 4.895.7 ± 4.7Lacourciere et al., 2001 \[[@CR25]\]148.7 ± 16.1148.9 ± 14.896.6 ± 5.296.4 ± 6.0Lacourciere et al., 2005 \[[@CR26]\]167.9 ± 8.0167.4 ± 8.3167.2 ± 7.993.2 ± 8.993.4 ± 9.693.7 ± 8.8Makita et al., 2009 \[[@CR27]\]160.6 ± 10.9162.5 ± 10.984.5 ± 7.886.1 ± 8.7Rhee et al., 2015 \[[@CR28]\]150.8 ± 12.7149.4 ± 11.996.8 ± 5.796.5 ± 5.428Sachse et al., 2002 \[[@CR29]\]156.0 ± 1.1155.3 ± 1.198.9 ± 0.499.9 ± 0.4MacKay et al., 1996 \[[@CR32]\]152.2152.6151.3100.9101.2101.7Sica et al, 2012 \[[@CR33]\]163164164165165165165164164959595959694969494Cushman et al, 2012 \[[@CR34]\]164.7 ± 9.9164.9 ± 10.1164.8 ± 9.895.2 ± 10.396.1 ± 9.895.9 ± 9.8Cushman et al, 2018 \[[@CR35]\]164.7 ± 10.4165.2 ± 11.1164.9 ± 10.596.1 ± 10.495.3 ± 10.595.4 ± 10.0Neutel et al., 2017 \[[@CR36]\]167.6 ± 7.0168.2 ± 7.195.7 ± 9.695.7 ± 9.2

ARB/HCTZ versus ARB {#Sec9}
-------------------

Data from 10 studies \[[@CR20]--[@CR29]\] with 1923 patients treated with ARB alone and 2720 patients treated with the combination ARB/HCTZ was used to estimate the effect of therapies on systolic blood pressure. Pooled results showed a weighted mean difference (WMD) of −6.89 (−8.09, −5.69) mmHg (Fig. [2](#Fig2){ref-type="fig"}) which is statistically significant (*p* = 0.02). *I*^2^ and *Q* values signify a moderate heterogeneity of results. Bias has been assessed (Figure S[1](#MOESM1){ref-type="media"} in Supplementary material). Fig. 2Forest plot for systolic blood pressure ARB/HCTZ versus ARB

Effect of ARB alone versus ARB/HCTZ on diastolic blood pressure was estimated on the basis of results from 11 studies \[[@CR20]--[@CR29], [@CR32]\]. Pooled results showed a WMD of −3.67 (−4.15, −3.19) mmHg (Fig. [3](#Fig3){ref-type="fig"}). The difference is in favor of the combination of ARB/HCTZ but it is statistically insignificant. *I*^2^ and *Q* values in this case are a marker for homogeneity and coherence among results (Fig. [3](#Fig3){ref-type="fig"} and Figure S[2](#MOESM1){ref-type="media"} in Supplementary material). Reductions in systolic and diastolic blood pressure can be considered clinically significant due to considerable reduction in the risk for cardiovascular complications \[[@CR37], [@CR38]\]. Fig. 3Forest plot for diastolic blood pressure ARB/HCTZ versus ARB

ARB/CTLD versus ARB {#Sec10}
-------------------

Only one article was found that compared the effect of the combination of ARB/CTLD on the systolic blood pressure to the effect of monotherapy with ARB. Sica et al. compared treatment with azilsartan medoxomil (AZL-M) 20 mg, 40 mg, or 80 mg; CTLD 12.5 or 25 mg; or 1 of the 6 combinations of these doses (AZL-M/CTLD: 20/12.5 mg, 40/12.5 mg, 80/12.5 mg, 20/25 mg, 40/25 mg, and 80/25 mg). Their primary endpoint was the change in systolic blood pressure determined by an ambulatory blood pressure measurement. The authors conclude that for the pooled AZL-M/CLD 40/25-mg and 80/25-mg FDC groups, SBP reduction by ABPM was 28.9 mmHg and exceeded AZL-M 80 mg and CLD 25 mg monotherapies by 13.8 mmHg and 13 mmHg, respectively (*p* \< .001 for both comparisons). They also comment that the incremental reduction in blood pressure for the combination containing 25 mg CTLD is significantly greater than what has previously been seen with an FDC containing 25 mg of HCTZ \[[@CR33]\].

ARB/CTLD versus ARB/HCTZ {#Sec11}
------------------------

Finally, we attempted to compare the effect of the two combinations on systolic and diastolic blood pressure in patients with hypertension. Only 3 studies were found that report results concerning changes in systolic blood pressure \[[@CR34]--[@CR36]\]. It should be noted that all of them are fairly recent, pointing out to a renewed interest in the potential of CTLD. Pooled results show a WMD of −6.30 mmHg (−7.30, −5.29) in favor of the combination containing CTLD (Fig. [4](#Fig4){ref-type="fig"}). *I*^2^ and *Q* values in this case are a marker for homogeneity and coherence among results (Figure S[3](#MOESM1){ref-type="media"} in Supplementary material). Fig. 4Forest plot for systolic blood pressure ARB/CTLD vs ARB/HCTZ

Same 3 studies report results concerning diastolic blood pressure \[[@CR34]--[@CR36]\]. Pooled WMD in this case is −3.57 mmHg (−4.17, 2.98) (Fig. [5](#Fig5){ref-type="fig"}) with prevalence for ARB/CTLD combination. *I*^2^ and *Q* values in this case are a marker for homogeneity and coherence among results (Figure S[4](#MOESM1){ref-type="media"} in Supplementary material). Both values for WMD in this case are statistically insignificant but can be considered clinically significant due to considerable reduction in the risk for cardiovascular complications \[[@CR37], [@CR38]\]. Fig. 5Forest plot for diastolic blood pressure ARB/CTLD vs ARB/HCTZ

Sensitivity analysis {#Sec12}
--------------------

Results from sensitivity analyses in relation to systolic and diastolic blood pressure for the comparisons ARB/HCTZ vs ARB and ARB/CTLD vs ARB/HCTZ respectively are presented in Tables S[2](#MOESM1){ref-type="media"} and S[3](#MOESM1){ref-type="media"} in the Supplementary material. When each study was subsequently excluded from the analysis, pooled WMD for systolic blood pressure for the ARB/HCTZ vs ARB comparison was in the range −7.23 to −6.59 mmHg while for diastolic blood pressure for the same comparison the range was −3.77 to −3.50 mmHg. Although studies have varying weights (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}), the subsequent exclusion of each study does not lead to significant change in results. The lack of substantial changes in WMD suggests consistency in findings and is a tentative confirmation of the possible prevalence for the combination compared to the monotherapy.

Pooled WMD for systolic blood pressure for the ARB/CTLD vs ARB/HCTZ comparison is presented in Table S[3](#MOESM1){ref-type="media"} in the Supplementary material and is in the range −6.54 to −6.15 mmHg. For the diastolic blood pressure, these values are in the range −3.80 to −3.35 mmHg. Studies have similar weights (Figs. [4](#Fig4){ref-type="fig"} and [5](#Fig5){ref-type="fig"}) and the variation in the values with subsequent exclusion of studies is very small. The results confirm the prevalence for the combination of ARB and CTLD.

Discussion {#Sec13}
==========

The combination of ARB and thiazide diuretics is highly effective for the treatment of hypertension and is well tolerated at the same time \[[@CR39], [@CR40]\]. This combination can be given as initial therapy (where appropriate) or later in the course of treatment \[[@CR4]\]. Most commonly, the ARB is combined with hydrochlorothiazide despite the existence of various diuretics \[[@CR40]\]. Recent studies suggest that chlorthalidone may be a suitable if not better alternative for hydrochlorothiazide \[[@CR34]--[@CR36], [@CR41]\]. NICE guidelines for the diagnosis and treatment of hypertension recommend ARB or angiotensin converting enzyme inhibitors as a starting regimen and advise the addition of thiazide-like diuretics as CTLD as opposed to hydrochlorothiazide \[[@CR42]\]. However, elderly patients with hypertension often have other comorbidities which require additional medications. Polypharmacy is associated with increased risk of adverse events (fall injury, hyperkalemia and hypokalemia, heart failure, and blood pressure exacerbation), polypharmacy mismanagement, drug-drug interaction, and increased costs \[[@CR43]\]. For such patients, treatment should be individualized and innovative approaches such as use of a fixed-dose combination pill, ingestible sensor system, electronic reminder system, medical audits, and the integration of a pharmacist in the care of patients should be implemented to avoid polypharmacy mismanagement \[[@CR43]\]. A retrospective observational medical chart review study suggests that adopting the clinical pharmacist's recommendations in a collaborative care approach could reduce the number of prescribed potentially inappropriate medications in patients aged 65 years or more therefore reducing the harmful drug-drug interactions and improving the adherence to treatment guidelines \[[@CR44]\]. Another study also suggests that a collaborative approach to address the risks of drug--drug interactions and that the potential use of drug--drug interaction checkers could be beneficial \[[@CR45]\].

Considering all said above, optimal control of blood pressure in hypertensive patients should be the goal. Although that may not always be achievable results of meta-analysis which used data from 147 randomized clinical trials showed that blood pressure reduction of 10 mmHg systolic and 5 mmHg diastolic was associated with a 41% (33 to 48%) reduction in stroke for all trials, 46% (35-55 %) in primary prevention trials, 44% (21-44 %) in secondary prevention trials, and 35% (20-47 %) in trials including subjects with a history of coronary heart disease \[[@CR37]\]. Other authors claim that even reductions of −2 mmHg can be considered clinically significant \[[@CR38], [@CR46]\].

Our analysis suggest as many have before us \[[@CR33], [@CR47]--[@CR52]\] that the combination of ARB and a thiazide diuretic is more effective for the control of systolic and diastolic blood pressure than the use of the ARB or diuretic alone. When it comes to a comparison between the combinations ARB/HCTZ and ARB/CTLD pooled results show a WMD of −6.30 mmHg (−7.30, −5.29) in favor of the combination containing CTLD for control of systolic blood pressure. A WMD of −3.57 mmHg (−4.17, 2.98) for control of diastolic blood pressure is in favor of CTLD again. Our results suggest a prevalence for CTLD over HCTZ when the two are combined with ARB and used for blood pressure reduction in patients with hypertension.

It should be noted that a certain degree of heterogeneity exists in the studies which were deemed eligible and were included in the analysis. This can be attributed to multiple factors such as variety of study design and outcomes; differences in the inclusion and exclusion criteria; the way of measuring BP; different ARBs used; and varying doses of diuretics. We have, however, attempted to determine the significance of those differences by performing sensitivity analysis.

Interest in CTLD was renewed of late. MRFIT is the first trial to suggest superiority of CTLD. Results from MRFIT show that replacement of HCTZ with CTLD might lead to lower coronary heart disease mortality \[[@CR53]\]. Dorsch et al. conducted a retrospective cohort analysis of MRFIT and concluded that after a follow-up period of 6 years cardiovascular events were less frequent in the CTLD group---21% lower than with HCTZ (*p* = 0.0016) \[[@CR54]\]. This estimation was confirmed by a network meta-analysis which declared that CTLD was better for preventing cardiovascular events in patients with hypertension reducing them by 21% \[[@CR10]\]. At the same time another observational cohort study does not find any association between reduction of cardiovascular events and CTLD use while at same time it shows an increase in the cases of electrolyte disturbances, specifically hypokalemia \[[@CR55]\]. We have also attempted to estimate the effect of the combination of CTLD and HCTZ with ARB on the serum levels of sodium and potassium. Only two studies \[[@CR35], [@CR36]\] reported data on levels of serum potassium. The WMD in this case was only 0.01 mEq/L suggesting lack of difference in the effect of the two combinations. Data for levels of serum sodium was unfortunately scarce.

There are several studies investigating the effect of CTLD and HCTZ on blood pressure. Greater reduction in SBP was recorded in a small randomized, single-blinded, crossover study comparing CTLD 12.5 mg/day (force-titrated to 25 mg/day) and HCTZ 25 mg/day (force-titrated to 50 mg/day) \[[@CR56]\] and in a double-blind, double-dummy, randomized, parallel group, comparative, multicentric trial \[[@CR57]\]. A meta-analysis comparing the dose response of HCTZ, CTLD, and bendroflumethiazide on blood pressure predicted that reduction of 10 mmHg of SBP could be achieved by 1.4, 8.6, and 26.4 mg of bendroflumethiazide, CTLD and HCTZ respectively \[[@CR58]\].

We evaluated a large number of sources in our attempt to examine the interchangeability of HCTZ and CTLD when they are used in combination with an ARB by assessing their effect on systolic and diastolic blood pressure. We tried to draw conclusions only by referring to trials we deemed to be of satisfactory quality (see [Supplementary material](#MOESM1){ref-type="media"}). Even though we used a lot of sources and included numerous patients in the analysis which is a prerequisite for reduction of bias we also used funnel plots in order to assess bias (see [Supplementary material](#MOESM1){ref-type="media"}). Additionally, we did not manage to find another paper be it a meta-analysis or a systematic review focusing on our topic and comparing the efficacy of the combination of angiotensin receptor blocker (ARB) and chlorthalidone (CTLD) to the combination of ARB and hydrochlorothiazide (HCTZ) in patients with hypertension.

There are a number of limitations intrinsic to the analysis. First of all, high quality trials investigating the efficacy of CTLD combined with ARB are scarce. Secondly, we have evaluated the effects of HCTZ and CTLD using data for combined doses. Almost all studies included in our statistical analysis were conducted relatively recently and all but two were funded by industry. Additionally, we did not take into consideration any existing comorbidities of the patients.

Conclusion {#Sec14}
==========

The combination of an ARB with a diuretic is a widely used method for addressing hypertension as a first or subsequent line of treatment. The most commonly used diuretic seems to be HCTZ. Our analysis suggests that CTLD should be considered as a valuable alternative for HCTZ and an option for fixed dose combinations with an ARB due to its tentative prevalence in blood pressure control when compared to HCTZ.
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